- Home
- GAM vs URGN Comparison
GAM vs URGN Comparison
Compare GAM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | URGN |
|---|---|---|
| Founded | 1927 | 2004 |
| Country | United States | United States |
| Employees | N/A | 253 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GAM | URGN |
|---|---|---|
| Price | $58.78 | $23.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 20.1K | ★ 773.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | ★ $96,516,000.00 |
| Revenue This Year | N/A | $27.96 |
| Revenue Next Year | N/A | $123.20 |
| P/E Ratio | $3.95 | ★ N/A |
| Revenue Growth | N/A | ★ 8.00 |
| 52 Week Low | $37.32 | $3.42 |
| 52 Week High | $46.48 | $30.00 |
Technical Indicators
Market Signals| Indicator | GAM | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 48.71 |
| Support Level | $58.43 | $22.60 |
| Resistance Level | $59.22 | $24.14 |
| Average True Range (ATR) | 0.70 | 1.17 |
| MACD | 0.18 | -0.09 |
| Stochastic Oscillator | 55.18 | 49.09 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.